Rosuvastatin Dosing for Known Heart Disease with Impaired Renal Function

Introduction to Rosuvastatin Dosing

• The American Heart Association recommends rosuvastatin 20-40 mg daily for patients with established heart disease and mild to moderate renal impairment (CrCl ≥30 mL/min) 4
• The American College of Cardiology suggests that patients with severe renal impairment (CrCl <30 mL/min) should start at 5 mg once daily and not exceed 10 mg daily 1

Dosing Algorithm Based on Renal Function

• For patients with severe renal impairment (CrCl <30 mL/min), the maximum safe dose of rosuvastatin is 10 mg daily due to 2-fold higher plasma concentrations 1
• The FDA recommends dose limitation to prevent myopathy and other adverse effects in patients with severe renal impairment 1

Intensity-Based Strategy for Heart Disease

• High-intensity therapy with rosuvastatin 20-40 mg daily achieves ≥50% LDL-C reduction and is recommended for established heart disease 4
• The 2021 AHA/ASA guidelines recommend rosuvastatin 20 mg daily as high-intensity statin therapy for patients with atherosclerotic cardiovascular disease 4
• Patients with known heart disease qualify as having major ASCVD events, placing them in the very high-risk category requiring aggressive LDL-C lowering 4

Special Considerations

• The AURORA trial demonstrated no cardiovascular benefit with rosuvastatin 10 mg in hemodialysis patients, leading to recommendations against new initiation 3
• Asian patients require a lower starting dose of 5 mg daily regardless of renal function due to 2-fold higher plasma concentrations 1

Critical Implementation Points

• The AHA/ASA guidelines recommend assessing LDL-C as early as 4 weeks after initiation and adjusting dosage accordingly 4
• If LDL-C remains elevated on maximally tolerated rosuvastatin, add ezetimibe before considering PCSK-9 inhibitors 4

Safety Profile in Renal Impairment

• Myopathy risk increases with renal impairment, age >65 years, hypothyroidism, and drug interactions—dose limitation to 10 mg daily in severe renal impairment mitigates this risk 2
• The American College of Cardiology suggests that treatment-related myopathy occurs in ≤0.1% of patients at recommended doses 2